1,150 results on '"Camps, C"'
Search Results
102. How sustainable are new treatment strategies for NSCLC?
103. Pharmacogenomics and gemcitabine
104. X-linked adrenoleukodystrophy in Spain. Identification of 26 novel mutations in the ABCD1 gene in 80 patients. Improvement of genetic counseling in 162 relative females
105. Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer
106. Time resolution of a photomultiplier readout system for space application
107. Epirubicin–cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study
108. Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non–Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial
109. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group
110. The design and construction of a double-sided Silicon Microvertex Detector for the L3 experiment at CERN
111. Erratum: Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival
112. Experience with the L3 vertex drift chamber at LEP
113. PHASE II TRIAL OF OXALIPLATIN-UFT-LEUCOVORIN (OXA-UFT-LV) COMBINATION IN FIRST-LINE TREATMENT OF ADVANCED COLORECTAL CANCER (ACC): Abstract 1148
114. Mutation burden and other molecular markers of prognosis in the QUASAR2 clinical trial of colorectal cancer treated with curative intent
115. Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects
116. Sweet syndrome as the leading symptom in the diagnosis of gastric cancer
117. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: Results from the ETOP Lungscape Project
118. Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease
119. Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project
120. PALB2 mRNA expression as a predictive marker in advanced non-small cell lung cancer (NSCLC) patients (p) treated with docetaxel-cisplatin
121. PALB2 mRNA expression as a predictive marker in advanced non-small cell lung cancer (NSCLC) patients (p) treated with docetaxel-cisplatin
122. EFFICIENCY OF THE GENOTYPING OF DPYD AND UGT1A1 IN THE PREVENTION OF SERIOUS SIDE EFFECTS TO TREATMENT IN COLON CANCER
123. MA04.03 Lung Tumorspheres Characterization Reveals Cancer Stem-Like Cells Potential Targets and Prognostic Markers in Non-Small Cell Lung Cancer
124. P2.05-12 Analysis of Biomarkers in Lung Cancer in Spain
125. Impact of burn-out syndrome in oncology personnel and its improvement through specific interventions
126. Characterization of lung tumourspheres reveals cancer stem-like cells potential targets and prognostic markers in non-small cell lung cancer
127. P2.03-38 Identification of a Novel Synthetic Lethal Vulnerability in Non-Small Cell Lung Cancer by Co-Targeting TMPRSS4 and DDR1
128. P1.09-13 Prognostic Value of TMPRSS4 Expression and Its Role as Diagnostic Biomarker by Liquid Biopsy in Early Stage NSCLC
129. P2.03-16 Agreement Between Different Methodologies for Non-Invasive p.T790M and EGFR Sensitizing Mutation Testing
130. Analysis of gut microbiota in advanced non-small cell lung cancer (NSCLC) patients treated with immune-checkpoints blockers
131. Prognostic value of CTCs in advanced NSCLC patients treated with platinum-based chemotherapy
132. Analysis of immunosuppressive factors produced by tumorspheres in NSCLC: Prognostic value of galectin-3 in adenocarcinoma
133. P2.03-08 Analysis of Immunosuppressive Factors Produced by CSCs Revealed Galectin-3 as Immune Modulator with Prognostic Value in NSCLC Adenocarcinoma
134. MA04.09 Study of Exosomes in NSCLC for Biomarkers Searching
135. P2.10-02 Smoking Habit in Lung Cancer in Spain
136. P1.03-15 Non-Invasive Detection of Secondary Resistance Mutations in ALK-Positive NSCLC Patients by Next-Generation Sequencing
137. P2.03-33 ctDNA Levels Significantly Predicts Survival in NSCLC Patients with an EGFR Activating Mutation
138. Exosomes in NSCLC: Analysis of its cargo as a source of biomarkers
139. Lung tumorspheres as a drug screening platform against cancer stem cells
140. Applicability of ctDNA at diagnosis and during the monitoring of EGFR-mutated patients
141. Survey of Hospital Quality
142. Optimisation du lambeau homodactyle digital en îlot sur l’artère collatérale par plastie en V ou double-V — étude anatomique
143. The burden of cancer in Spain
144. Design and construction of the prototype synchrotron radiation detector
145. Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen
146. The Alpha Magnetic Spectrometer (AMS) on the International Space Station: Part I – results from the test flight on the space shuttle
147. Testing of FE Hybrids and Si detector modules for the CMS Tracker
148. The Alpha Magnetic Spectrometer (AMS)
149. Estudio de la astenia tumoral: constitución del grupo ASTHENOS
150. DIFERENCIAS ENTRE LA PSICOMOTRICIDAD DINÁMICA Y NORMATIVA EN EL DESARROLLO INFANTIL.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.